American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) positioned DPP-4i alongside with sulfonylureas, thiazolidinediones, GLP-1 agonists and insulin, as a second-line add-on to metformin in their general recommendation [8]. This evidence concerns the gene INS and diabetes mellitus.